Alexander Slotwiner, MD
Interventional Cardiology · New York, NYNPI 1831309517
Payments from drug & device makers
Across 243 payments — averaging $92.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$11K
- Abbott$3K
- Medtronic$2K
- Shockwave Medical, Inc$2K
- Abiomed$1K
- Johnson & Johnson$716
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$9,06340%
- Travel & lodging$1821%
- Food & beverage$13,30159%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 32 | $10,801 |
| Abbott | 50 | $2,529 |
| Medtronic(2 entities) | 74 | $2,152 |
| Shockwave Medical, Inc | 13 | $1,544 |
| Abiomed | 11 | $1,460 |
| Johnson & Johnson | 9 | $716 |
| Atricure, Inc. | 3 | $407 |
| EBR Systems, Inc. | 1 | $330 |
| Inari Medical, Inc. | 2 | $256 |
| Pfizer | 7 | $185 |
| Novartis | 8 | $180 |
| Penumbra, Inc. | 3 | $178 |
| Recor Medical Inc | 1 | $170 |
| Philips North America LLC | 2 | $152 |
| Cardiovascular Systems Inc. | 2 | $150 |
| Endologix LLC | 1 | $150 |
| Esperion Therapeutics, Inc. | 1 | $150 |
| Boehringer Ingelheim | 2 | $148 |
| Terumo Medical Corporation | 1 | $147 |
| Biotronik Inc. | 1 | $134 |
| Amgen | 5 | $117 |
| Artivion, Inc. | 1 | $117 |
| Cook Medical LLC | 1 | $92 |
| E.r. Squibb & Sons, L.L.C. | 3 | $76 |
| Spectrawave, Inc | 1 | $65 |
| Merck | 3 | $42 |
| Cordis US CORP. | 2 | $33 |
| Avinger Inc. | 1 | $32 |
| Angiodynamics, Inc. | 1 | $16 |
| AstraZeneca | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL VASCULAR INTERVENTION$4,063
- ELUVIA$2,667
- OPTICROSS$2,500
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,374
- Impella$1,310
- SYMPLICITY G3$838
- XARELTO$472
- Xience Sierra Coronary Stent$364
- AVEIR$343
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$315
- Dragonfly OCT$259
- GENERAL - STENTS$258
- FLOWTRIEVER CATHETER, S$256
- CT THROMBECTOMY SYSTEM KIT$256
- OPTIS$245
- HawkOne$227
- EMBOSHIELD NAV6$193
- ESPRIT$175
- Paradise Ultrasound Renal Denervation System$170
- ROTAPRO$169
How this compares
$22,545 in reported general payments places this provider in the 60th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 451 | $519,889 |
| XareltoRivaroxaban | 128 | $143,015 |
| EntrestoSacubitril/Valsartan | 76 | $107,113 |
| JardianceEmpagliflozin | 34 | $52,199 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $42,784 |
| FarxigaDapagliflozin Propanediol | 26 | $31,359 |
| BrilintaTicagrelor | 25 | $22,843 |
| Repatha PushtronexEvolocumab | 19 | $11,500 |
| Metoprolol Succinate | 684 | $8,981 |
| Sildenafil Citrate | 16 | $8,052 |
| Atorvastatin Calcium | 634 | $7,040 |
| TradjentaLinagliptin | 13 | $6,531 |
| Rosuvastatin Calcium | 375 | $5,630 |
| Ranolazine ErRanolazine | 68 | $4,418 |
| ClopidogrelClopidogrel Bisulfate | 427 | $3,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $185 | $519,889451 claims |
| Johnson & JohnsonXarelto | $716 | $143,015128 claims |
| NovartisEntresto | $180 | $107,11376 claims |
| Boehringer IngelheimJardiance, Tradjenta | $148 | $58,73147 claims |
| AstraZenecaFarxiga, Brilinta | $16 | $54,20251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Martin LeonNew York$13.5M
- Susheel KodaliNew York$6M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
- George DangasNew York$2.6M
- Prakash KrishnanNew York$2M
- Ajay KirtaneNew York$1.8M
- Shing-Chiu WongNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.